Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

141-160 of 991 trials

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteOncology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemotePulmonology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteOrthopedics and TraumatologyPediatrics

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Daridorexant for Insomnia in Alzheimer's Patients

We are studying whether daridorexant can improve sleep quality in individuals with mild cognitive impairment and mild to moderate Alzheimer's disease. This trial aims to evaluate its effects on sleep duration, daytime functioning, and overall health.

Insomnia Disorder>2 yearsMonitoring phase (IV)6-10 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementNeurologyPsychiatry

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Type 2 Diabetes: BCAA Oxidation Study

We are investigating whether boosting branched-chain amino acid oxidation can lower blood sugar levels in people with type 2 diabetes. The study also examines effects on insulin sensitivity, heart health, and cognitive function.

Type 2 Diabetes6-12 monthsMonitoring phase (IV)6-10 visits No Placebo Standard Medicines Cost ReimbursementDiabetologyEndocrinology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyHepatology

Knee Cartilage Defects: Stem Cell Treatment Study

We are testing whether a combination of stem cells and a 3D scaffold improves healing in knee cartilage defects compared to standard treatment. This study also looks at the safety of using these stem cells.

Knee Cartilage Defect>2 yearsEfficacy phase (II)No Placebo Investigational Medicines Cost ReimbursementOrthopedics and TraumatologyRheumatology

Metastatic Non-Small Cell Lung Cancer: Pembrolizumab with Sacituzumab Govitecan

We are studying whether combining pembrolizumab with sacituzumab govitecan improves survival and quality of life for patients with metastatic non-small cell lung cancer. This trial compares the combination treatment to pembrolizumab alone.

Metastatic Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)No Placebo Standard Medicines Cost ReimbursementOncology

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteAllergologyHematology

Lung Cancer: Adagrasib Dosing Study

We are comparing two dosing schedules of adagrasib for patients with non-small cell lung cancer and a KRAS G12C mutation who have had previous treatments. The goal is to find out which regimen works better and is safer.

Non-small cell lung cancerEfficacy phase (II)No Placebo Standard Medicines Cost ReimbursementOncology

Melatonin for Chronic Back Pain

We are studying whether melatonin can help reduce pain and improve sleep in people with chronic back pain. This trial compares melatonin to a placebo to see which is more effective.

Chronic Back Pain≤3 monthsConfirmation phase (III)≤5 visits Standard Medicines Cost ReimbursementInternal MedicineOrthopedics and Traumatology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Pulmonary Arterial Hypertension: Seralutinib Inhalation Study

We are studying whether inhaling seralutinib helps improve exercise capacity in people with pulmonary arterial hypertension. The trial also looks at safety and other health benefits compared to a placebo.

Pulmonary Arterial Hypertension1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementCardiologyPulmonology

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

Systemic Lupus Erythematosus: Upadacitinib Study

We are investigating whether the oral medication upadacitinib can improve symptoms in adults with moderate to severe systemic lupus erythematosus. The study will also monitor its safety over time compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Search Clinical Trials in the European Union